Peer Review History

Original SubmissionJune 8, 2021
Decision Letter - Anjani Kumar Tiwari, Editor

PONE-D-21-18913

Differential mitochondrial protein interaction profile between human translocator protein and its A147T polymorphism variant

PLOS ONE

Dear Dr. Ittner,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 10 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Anjani Kumar Tiwari, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please update your submission to use the PLOS LaTeX template. The template and more information on our requirements for LaTeX submissions can be found at http://journals.plos.org/plosone/s/latex.

3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

4. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

This works was supported by funding from the National Health and Medical Research Council 

13 and the Australian Research Council to M.K., Y.D.K. and L.M.I..

We note that you have provided additional information within the Acknowledgements Section that is not currently declared in your Funding Statement. Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 

5. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. 

  

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

Additional Editor Comments:

This is very good attempt to see the interactions, but results are not very promising. Further supporting data are required . Author may give insights of additional studies if possible and should add a detailed future studies required in this directions. It will help to those who are trying to establish new insights for this protein in different pathological conditions.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript of the paper entitled "Differential mitochondrial protein interaction profile between human translocator protein and its A147T polymorphism variant' is presented in a proper manner. However, author should consider following corrections before resubmission:

1.Page 10, L16 replace ‘cOmplete with ‘complete’

2.Page 10, L17; Page 10, L 22; Page 11, L 6, replace ‘))’ with ‘)’

3.Page 11, L 13 replace ‘inhibitor .’ with ‘inhibitor.’

4.Maintain consistency in units such as 50 mM instead of 50mM, 4oC instead of 4o C, min instead of Minutes, h instead of hour, either mL or ml, g instead of gram, 10 cm instead of 10cm, μl instead of microlitres etc

5.Page 12, L 13-15, L16-18 correct the sentences

6.Page 17, L12-14, reframe the sentence

7.Page 20, line 8, Replace ‘experiments .’ with ’experiments.’

I found the experiments were executed in a planned way. Technically manuscript is good.

Reviewer #2: An interesting research work by Lars M Ittner and team.

This is first such study to see interaction profile between human translocator protein and its A147T polymorphism variant.

In summary, the results identified the loss of a subset of interaction partners with the 6 A147T polymorphism variant of human TSPO but one of the positive aspects seems

"TSPO’s interaction with YWHAQ 7 might contribute to the regulation of TSPO’s targeting into mitochondrial membranes involved 8 in apoptotic signaling pathways"

Does author further support it by additional evidence.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Dr Pooja Srivastava

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Point-to-point response to reviewer comments

We thank both reviewers for their comments that have been addressed as indicated below. We hope you find the revised version of the manuscript ready for publication in PLOS ONE.

Reviewer #1: The manuscript of the paper entitled "Differential mitochondrial protein interaction profile between human translocator protein and its A147T polymorphism variant' is presented in a proper manner. However, author should consider following corrections before resubmission:

1.Page 10, L16 replace ‘cOmplete with ‘complete’

2.Page 10, L17; Page 10, L 22; Page 11, L 6, replace ‘))’ with ‘)’

3.Page 11, L 13 replace ‘inhibitor .’ with ‘inhibitor.’

4.Maintain consistency in units such as 50 mM instead of 50mM, 4oC instead of 4o C, min instead of Min, h instead of h, either mL or ml, g instead of gram, 10 cm instead of 10cm, μl instead of microlitres etc

5.Page 12, L 13-15, L16-18 correct the sentences

6.Page 17, L12-14, reframe the sentence

7.Page 20, line 8, Replace ‘experiments .’ with ’experiments.’

Response: We thank this reviewer for the detailed comments and have made the requested changes. All changes have been highlighted in the marked version of the revised manuscript for your convenience.

I found the experiments were executed in a planned way. Technically manuscript is good.

Response: This is very much appreciated.

Reviewer #2: An interesting research work by Lars M Ittner and team.

This is first such study to see interaction profile between human translocator protein and its A147T polymorphism variant.

In summary, the results identified the loss of a subset of interaction partners with the 6 A147T polymorphism variant of human TSPO but one of the positive aspects seems

"TSPO’s interaction with YWHAQ 7 might contribute to the regulation of TSPO’s targeting into mitochondrial membranes involved 8 in apoptotic signaling pathways"

Does author further support it by additional evidence.

Response: We have carefully reworded this sentence to indicate that future investigation is needed to provide direct evidence. It reads now: “Based on DAVID Functional Clustering enrichment analysis, a possible role of the TSPO’s interaction with YWHAQ could be the regulation of TSPO’s targeting into mitochondrial membranes involved in apoptotic signaling pathways. But future studies are required to provide direct evidence.”

Attachments
Attachment
Submitted filename: PtP letter revision.pdf
Decision Letter - Anjani Kumar Tiwari, Editor

Differential mitochondrial protein interaction profile between human translocator protein and its A147T polymorphism variant

PONE-D-21-18913R1

Dear Author

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Anjani Kumar Tiwari, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

This form of manuscript is ok for publication.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: N/A

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: No

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: As i can see that nearly all the questions asked by experts have been replied in revised manuscript therefore in my opinion Academic Editor may permit for publication in PLOS ONE

Reviewer #3: All the queries raised by previous reviewers have been replied, therefore it can be considered for publication in PLOS One.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

Formally Accepted
Acceptance Letter - Anjani Kumar Tiwari, Editor

PONE-D-21-18913R1

Differential mitochondrial protein interaction profile between human translocator protein and its A147T polymorphism variant

Dear Dr. Ittner:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Anjani Kumar Tiwari

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .